Wraparound Fundraising May 2012

LLS is focused on cures While other large cancer organizations target their mission investment on prevention and early detection, LLS invests in cures because most blood cancers cannot be prevented or detected early.

Research is the cancer answer LLS has been funding research for more than 60 years and has a remarkable record of supporting investigations that lead to improved diagnostics and more effective therapies. Today, LLS funds more blood cancer research than any other voluntary health agency in the U.S. or Canada.

Blood cancers are the #3 cancer killer in North America Only cancers of the respiratory and digestive systems, including lung and colon cancers, are more deadly.

Why does blood cancer research have such a big impact? Studies of “liquid” versus “solid” cancers can be easier and more productive, leading to laboratory and clinical breakthroughs. Blood cancer research produced the first broadly effective chemotherapies and the first successes in molecularly targeted therapies. Almost half of the new cancer drugs approved in the U.S. since 2000 (21/50) were approved to treat one or more blood cancer, and LLS helped advance most of them.

Blood cancer research is a gateway to helping many patients As we learn more about different cancers, we are finding similarities. This means that many drugs developed for patients with a particular blood cancer can help more patients, including patients with other blood cancers, solid tumors and serious non-malignant diseases.

LLS research funding has played a vital role in many far-reaching advances. For example: l The antibody drug Rituxan®, is approved as a treatment for patients with forms of B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia, and for patients with rheumatoid arthritis. And it’s in late stage testing for patients with other autoimmune diseases and to prevent rejection after organ transplantation. The targeted drug, Gleevec®, is approved for patients with chronic myelogenous leukemia, a form of acute lymphocytic leukemia and rare forms of skin and stomach cancers. This drug and the newer drugs, Sprycel® and Tasigna®, are showing promise for patients with breast, prostate, lung and pancreatic cancer, melanoma and other cancers. Another targeted drug, Revlimid®, is approved for patients with myelodysplastic syndromes and for myeloma patients. It’s now in clinical efficacy trials for lymphoma and leukemia patients and for patients with bladder, brain, ovarian, prostate and other cancers.

LLS is driving innovative research Even with decades of LLS-supported progress, there are still patients who urgently need more effective and safer treatments. LLS is proactively funding academic research in areas of unmet medical need and partnering with companies to accelerate promising new therapies through essential clinical trials. For example: l LLS actively solicits research proposals focused on making today’s curative therapies safer, identifying patients at risk of developing serious long- term side effects and developing strategies to prevent or reduce the damage. With LLS support, a clinical trial in Los Angeles is testing an approach to reduce bone damage after anti-cancer steroid treatments.

Through our Therapy Acceleration Program, LLS is partnered with Acetylon Pharmaceuticals, Inc. to support early clinical testing of a new drug for myeloma patients. This drug can reverse specific abnormalities that can alter gene activities to cause a wide range of cancers. Avila Therapeutics, Inc. was developing a new drug for rheumatoid arthritis patients, but LLS knew that it might also help patients with B-cell cancers. Thanks to LLS funding, this drug entered clinical testing for these patients. Early findings are so positive that Celgene Corporation recently acquired Avila to expand their pipeline of promising oncology drugs. Also through Therapy Acceleration, LLS is advancing a new drug for acute myeloid leukemia (AML) patients. This drug came out of grant- funded work in Toronto that showed an old anti-fungal drug could be a powerful new anti-cancer treatment. The drug was reformulated for oral use and is looking good in a clinical trial.

Wraparound Events Additional ways to raise funds towards your Leukemia Cup participation Funds raised count toward incentives/Fantasy Sail qualifying

Examples of Wraparounds Sailboat icon sales Bake Sales Garage Sales Auctions Ad Space on your boat “Crew for Hire” Ice Cream Social Bowlathon LLS Candy Bar

Sailboat Icons

Sailboat Icons Sales Outlets Local businesses Your Office Restaurants/Bars near sailing venues Marine/Sailing Supplies –West Marine Caveat

LLS Candy Bar

Cost per box is $14.00 (this includes all local and state tax) Shipping cost are not included in the $14.00 Orders can be shipped to home or business locations with UPS delivery in 7 to 10 days from the date of the order Recommended selling price per bar is $2, which equates to almost $60 in profit on a two-box order Almonds are non-allergenic and the chocolate is kosher Payment is made at the time of the order and the site accepts MasterCard, Visa and American Express

Next Webcast June 4 – 3 pm Eastern – Gary Jobson Google+ Hangout July 10 – 3 pm Eastern - Local Event Sponsorships/Involving the entire sailing community